Cross-licensing deal expands Amersham's market
This article was originally published in Clinica
Executive Summary
Amersham, the UK healthcare and life sciences group, announced an important cross-licensing agreement at the same time as reporting strong first-half results. The cross-licensing deal gives Amersham patent access to Roche's thermostable enzymes for sequencing, terminator chemistry (DuPont patents) and four colour process chemistry (Caltech patents) in return for patent access to Amersham's thermostable enzymes for sequencing (Harvard and Amersham patents).